Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123772 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers
A Phase 1 study, sponsored by Inotek Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT01123772 is a Phase 1 study that has completed, run by Inotek Pharmaceuticals Corporation. The registered enrollment target is 70 participants.
The verdict
NCT01123772, a Phase 1 study, has completed, sponsored by Inotek Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how tolerable and safe it is to give INO-8875 eye drops at different concentrations to normal older healthy adult volunteers for two weeks.
Interventions
- DRUG INO-8875
- OTHER Placebo control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01123772
The ClinicalTrials.gov registry entry for NCT01123772 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inotek Pharmaceuticals Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which INO-8875 is the first listed.
NCT01123772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01123772 about?
NCT01123772 is a clinical study titled "Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers". The purpose of this study is to evaluate how tolerable and safe it is to give INO-8875 eye drops at different concentrations to normal older healthy adult volunteers for two weeks.
What is the current status of trial NCT01123772?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2010-05. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01123772?
The interventions under investigation include: INO-8875 (DRUG), Placebo control (OTHER).
Who is sponsoring clinical trial NCT01123772?
This trial is sponsored by Inotek Pharmaceuticals Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.